|By PR Newswire||
|February 28, 2014 07:00 AM EST||
TOKYO, Feb. 28, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full responsibility for manufacturing isavuconazole in the U.S. and Canada.
Basilea assumes full rights to isavuconazole in the rest of the world in return for waiving its right to co-promote the product in the U.S. and Canada. The original agreement was executed in February 2010. Under the amended agreement, the submission of the New Drug Application (NDA) and potential approval in the U.S. will continue to be subject to the payment of a development milestone by Astellas. In addition, the conditions regarding sales milestone payments have been changed. Accordingly, the total amount of the development and sales milestones that Astellas is subject to paying Basilea is CHF 374 million.
Astellas will continue its collaborative relationship with Basilea on the development of isavuconazole to provide a new therapeutic option for the treatment of serious fungal infections to patients in the U.S. and Canada.
SOURCE Astellas Pharma US, Inc.
Aug. 25, 2016 03:30 AM EDT Reads: 2,110
Aug. 25, 2016 02:30 AM EDT Reads: 2,140
Aug. 25, 2016 02:15 AM EDT Reads: 457
Aug. 25, 2016 02:00 AM EDT Reads: 1,776
Aug. 25, 2016 02:00 AM EDT Reads: 1,891
Aug. 25, 2016 01:15 AM EDT Reads: 1,602
Aug. 25, 2016 01:00 AM EDT Reads: 1,972
Aug. 25, 2016 12:45 AM EDT Reads: 1,903
Aug. 25, 2016 12:30 AM EDT Reads: 2,073
Aug. 25, 2016 12:00 AM EDT Reads: 2,975
Aug. 24, 2016 10:30 PM EDT Reads: 1,458
Aug. 24, 2016 10:30 PM EDT Reads: 2,012
Aug. 24, 2016 09:15 PM EDT Reads: 1,673
Aug. 24, 2016 04:45 PM EDT Reads: 1,326
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
Aug. 24, 2016 04:15 PM EDT Reads: 2,559